Tech Company Financing Transactions

Ayala Pharmaceuticals Funding Round

On 5/29/2019, Ayala Pharmaceuticals received $30 million in Series B funding from Novartis Venture Fund, aMoon Partners and Harel Insurance.

Transaction Overview

Announced On
5/29/2019
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Proceeds Purpose
The new capital will fuel Ayala's plans to advance the clinical development of lead product candidate AL101, a pan-Notch inhibitor that is currently being evaluated for adenoid cystic carcinoma (ACC).

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1313 N. Market St. 5100
Wilmington, DE 19801
USA
Email Address
Overview
Ayala (Nasdaq: AYLA) is a clinical stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers. We look to target rare and unique cancers, in which the Notch activation pathway has been dysregulated. Notch is a proven oncogenic driver in defined cancers.
Profile
Ayala Pharmaceuticals LinkedIn Company Profile
Social Media
Ayala Pharmaceuticals Company Twitter Account
Company News
Ayala Pharmaceuticals News
Facebook
Ayala Pharmaceuticals on Facebook
YouTube
Ayala Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Roni Mamluk
  Roni Mamluk LinkedIn Profile  Roni Mamluk Twitter Account  Roni Mamluk News  Roni Mamluk on Facebook
Chief Financial Officer
Yossi Maimon
  Yossi Maimon LinkedIn Profile  Yossi Maimon Twitter Account  Yossi Maimon News  Yossi Maimon on Facebook
Chief Medical Officer
Andrea Vergara-Silva
  Andrea Vergara-Silva LinkedIn Profile  Andrea Vergara-Silva Twitter Account  Andrea Vergara-Silva News  Andrea Vergara-Silva on Facebook
Vice President
David Caron
  David Caron LinkedIn Profile  David Caron Twitter Account  David Caron News  David Caron on Facebook
VP - Bus. Development
Dana Gelbaum
  Dana Gelbaum LinkedIn Profile  Dana Gelbaum Twitter Account  Dana Gelbaum News  Dana Gelbaum on Facebook
VP - Human Resources
Irit Klipper-Avni
  Irit Klipper-Avni LinkedIn Profile  Irit Klipper-Avni Twitter Account  Irit Klipper-Avni News  Irit Klipper-Avni on Facebook
VP - R & D
Joel Kaye
  Joel Kaye LinkedIn Profile  Joel Kaye Twitter Account  Joel Kaye News  Joel Kaye on Facebook


 

 

Browse more venture capital transactions:

Prev: 5/29/2019: New Energy Equity venture capital transaction
Next: 5/29/2019: Medically Home venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary